Skip to main content
Loading

Disease heterogeneity as a barrier to reliable biomarker development in CNS therapeutics

10 Sept 2026
Biomarkers
Industry Expert
Jeremy Linsley, Co-Founder/CSO - Stealth Mode Biotech